Press release
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI™ NDA under
About this update from United Therapeutics Corporation
[{"type":"text","content":"Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year\n Tyvaso DPI™ NDA under review with FDA action expected in October 2021\n\n\nSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021 grew 23% year over year to $446.5 million, compared to $362.0 million in the second quarter of 2020. \n\"We are pleased to continue our expansion into new indications outside of WHO Group 1 PAH with strong Tyvaso financial results, and with patient enrollment continuing in our PERFECT and TETON phase 3 studies in COPD-associated pulmonary hypertension and in IPF, respectively,\" said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. \"Meanwhile, we are also focused on expanding our medical armamentarium for PAH with the continued progress of our phase 3 studies of once-daily ralinepag, and with our next-generation treprostinil molecules and delivery systems.\" \n\"As we build traction with the Tyvaso PH-ILD launch, I am also tremendously excited about the uptake of all of our products during the past quarter,\" said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. \"Indeed, we are currently seeing some of the highest levels of referrals of Tyvaso and Orenitram since their launches and we're well on our way to our goal of doubling the number of Tyvaso patients on therapy by the end of 2022.\"\nSECOND QUARTER 2021 FINANCIAL RESULTS \nKey financial highlights include (dollars in millions, except per share data):\n\nThree Months Ended \nJune 30,\nDollarChange\nPercentageChange\n2021\n2020\nRevenues\n$\n446.5\n$\n362.0\n$\n84.5\n23\n%\nNet income\n$\n172.6\n$\n107.1\n$\n65.5\n61\n%\nNon-GAAP earnings(1)\n$\n193.5\n$\n163.2\n$\n30.3\n19\n%\nNet income, per basic share\n$\n3.85\n$\n2.43\n$\n1.42\n58\n%\nNet income, per diluted share\n$\n3.65\n$\n2.41\n$\n1.24\n51\n%\nNon-GAAP earnings, per diluted share(1)\n$\n4.09\n$\n3.68\n$\n0.41\n11\n%\n(1)\nSee definition of non-GAAP earnings, a non-GAAP financial measure, and a reconciliation of net income to non-GAAP earnings below.\nRevenues\nThe table below summarizes the co...